HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Daniel J. Goldstein Mehmet C. Oz Craig R. Smith Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldstein, D. J. Articles by Delphin, E. Search for Related Content PubMed PubMed Citation Articles by Goldstein, D. J. Articles by Delphin, E.

Ann Thorac Surg 1996;61:692-695
© 1996 The Society of Thoracic Surgeons

---

Original Article: Cardiovascular

Safety of Repeat Aprotinin Administration for LVAD Recipients Undergoing Cardiac Transplantation

Departments of Surgery and Anesthesiology, College of Physicians & Surgeons, Columbia University, New York, New York

Accepted for publication October 18, 1995.

Background. Anecdotal reports of allergic and anaphylactic reactions after aprotinin therapy have raised concern that its repeat use may be associated with substantial morbidity.

Methods. To address this concern, we reviewed our experience with all patients who underwent implantation of a left ventricular assist device and subsequent cardiac transplantation with perioperative use of aprotinin.

Results. Twenty-three patients received full-dose aprotinin during left ventricular assist device implantation and subsequent cardiac transplantation. All patients tolerated primary exposure to aprotinin without complication. One episode of anaphylaxis after secondary exposure was treated with rapid institution of cardiopulmonary bypass. Although renal dysfunction was observed shortly after cardiac transplantation in 30.4% of patients, the effect was transient and occurred in the presence of cyclosporine. The one perioperative death after secondary exposure was unrelated to bleeding complications. No clinically evident thromboembolic events were documented.

Conclusions. Primary and secondary exposure to aprotinin during operation with cardiopulmonary bypass is associated with limited intraoperative blood use, a low incidence of transient renal dysfunction and anaphylaxis, a rare need of reoperation for bleeding, and no clinical thromboembolic events.

This article has been cited by other articles:

				J. R. Cooper Jr, J. Abrams, O.H. Frazier, R. Radovancevic, B. Radovancevic, A. W. Bracey, M. J. Kindo, and I. D. Gregoric Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: Possible association with antifibrinolytic therapy J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 963 - 968. [Abstract] [Full Text] [PDF]

				J. J. Magner and D. Royston Heart failure Br. J. Anaesth., July 1, 2004; 93(1): 74 - 85. [Abstract] [Full Text] [PDF]

				D. J. Goldstein and R. B. Beauford Left ventricular assist devices and bleeding: adding insult to injury Ann. Thorac. Surg., June 1, 2003; 75(90060): S42 - 47. [Abstract] [Full Text] [PDF]

				M. J. Ray, K. F. Brown, C. A. Burrows, and M. F. O Brien Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass Ann. Thorac. Surg., September 1, 1999; 68(3): 940 - 945. [Abstract] [Full Text] [PDF]

				T. L. Spray Use of Aprotinin in Pediatric Organ Transplantation Ann. Thorac. Surg., June 1, 1998; 65(90060): S71 - 73. [Abstract] [Full Text] [PDF]

				S. Westaby Aprotinin Fifteen Years Later Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 366 - 375. [Abstract] [PDF]